CD274 and neoplasm: Future prospective studies are still needed to evaluate the integration of these biomarkers with other potential factors (e.g., TILs with PD-L1 or TMB) and, in turn, to explore more precise biomarkers of efficacy for tumor immunotherapy using standardized methods and thresholds, such as liquid biopsy-based analysis.